Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.

Currently Recruiting

  • Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering

    This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

    This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

    Eligible Tumour Type(s): Acute Myeloid Leukemia (AML)
    Sponsor: In-House
    Principal Investigator: Dr Mark Minden
    NCT#: NCT02483312

    https://clinicaltrials.gov/ct2/show/NCT02483312
  • Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)
    Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Fallopian Tube Tumours, Malignant Pleural Mesothelioma, Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Squamous Cell Carcinoma of the Oral Cavity, Triple Negative Breast Cancer
    Sponsor: In-house
    Principal Investigator: Lillian Siu & Anna Spreafico(Second PI)
    NCT#: NCT03686202

    https://clinicaltrials.gov/ct2/show/NCT03686202
  • Tumor Immunotherapy and MicrobiomE Analysis Project (TIME)
    Eligible Tumour Type(s): Metastatic Melanoma
    Sponsor: In-house
    Principal Investigator: Marcus Butler
    NCT#: N/A
  • Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in PatiEnts with Advanced Solid TumoRs (DAPPER)
    Eligible Tumour Type(s): Colorectal Cancer, Leiomyosarcoma, Pancreatic Adenocarcinoma
    Sponsor: In-house
    Principal Investigator: Lillian Siu
    NCT#: NCT03851614

    https://clinicaltrials.gov/ct2/show/NCT03851614
  • Prospective Analysis of INteStinal Microbiome and Autoimmune PanEls as PrediCtors of Toxicity in Phase I ImmunOncology Patients (INSPECT-IO)
    Eligible Tumour Type(s): Solid Cancer
    Sponsor: In-house
    Principal Investigator: Anna Spreafico
    NCT#: NCT04107311

    https://clinicaltrials.gov/ct2/show/study/NCT04107311
  • LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers (LANDMARC)
    Eligible Tumour Type(s): Epstein-Barr virus- and human papillomavirus -related cancers, Hepatocellular carcinoma
    Sponsor: In-house
    Principal Investigator: Kathy Han
    NCT#: NCT04665388

    https://clinicaltrials.gov/ct2/show/NCT04665388
  • Role of Microbiome as a Biomarker in Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma 2 (ROMA LA-OPSCC-2)
    Eligible Tumour Type(s): Locoregionally-Advanced Oropharyngeal Squamous Cell Carcinoma
    Sponsor: In-house
    Principal Investigator: Anna Spreafico
    NCT#: NCT03838601

    https://clinicaltrials.gov/ct2/show/NCT03838601
  • 1301-02

    Phase 1b Study of NY-ESO-1 specific TCR gene transduced autologous T lymphocytes in patients with solid tumors

    Eligible Tumour Type(s): Solid Cancer
    Sponsor: In-house (in collaboration with Takara Bio Inc)
    Principal Investigator: Marcus Butler
    NCT#: NCT02869217

    https://clinicaltrials.gov/ct2/show/NCT02869217

Closed Recruiting

  • INSPIRE

    INvestigator-initiated Phase II Study of pembrolizumab immunological response evaluation

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Triple Negative Breast Cancer
    Sponsor: In-House
    Principal Investigator: Lillian Siu
    NCT#: NCT02644369

    https://clinicaltrials.gov/ct2/show/NCT02644369
  • ACTIVATE

    Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT02811497

    https://clinicaltrials.gov/ct2/show/NCT03158935

Pages